Abstract:<p>While many patients with psoriasis are candidates for topical agents, long-term treatment effects are unclear. This systematic review evaluated global findings from clinical trials and real-world studies of topical calcipotriol and the two-compound formulation of calcipotriol and betamethasone dipropionate for mild-to-moderate plaque psoriasis (including scalp psoriasis). PubMed, Embase and MEDLINE were searched for relevant English-language publications along with Chinese, Japanese, Korean and Latin American publication databases. Identified articles were screened by title and abstract against predefined inclusion/exclusion criteria. A narrative synthesis of key efficacy and safety findings from the full papers of selected publications was developed. Thirty-seven relevant papers were identified (25 English, 11 Chinese and one Japanese-language study) including 28 randomized controlled trials. While there was significant heterogeneity in study length, treatment intensity and clinical measures, following a critical review of the published data combined with expert opinion, the following clinical practice recommendations were agreed in order to assist healthcare providers: in adults, long-term treatment with calcipotriol/betamethasone dipropionate is well tolerated and efficacious for up to 1 year on an 'as needed' basis, and for up to 16 weeks on a fixed-treatment regimen. Calcipotriol is also well tolerated and efficacious when used long term (up to 52 weeks) 'as needed' and for up to 20 weeks on a fixed-treatment regimen. Used on an 'as needed' basis for up to 1 year, the safety and efficacy profile of fixed-dose combination calcipotriol/betamethasone dipropionate is more favorable than calcipotriol alone; regular consultation between patients and their dermatologist/primary care physician is required to review psoriasis symptoms and adjust treatment accordingly; a specific treatment goal should be agreed on initiation of topical agent(s) to determine when long-term treatment can begin or if a regimen change is warranted; and application frequency during the continued treatment phase should consider the patients' treatment expectations and goals.</p>

Low systemic exposure and calcemic effect of calcipotriol/betamethasone ointment in rats with imiquimod-induced psoriasis-like dermatitis

Topical Treatment of Calcipotriol Decreases Expression of ICAM-3 Positive Infiltrating Leukocytes in Psoriatic Skin

The vitamin D3 analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production

An Investigator‐masked Comparison of the Efficacy and Safety of Twice Daily Applications of Calcitriol 3 Μg/g Ointment Vs. Calcipotriol 50 Μg/g Ointment in Subjects with Mild to Moderate Chronic Plaque‐type Psoriasis

Calcipotriol Betamethasone Ointment in the Treatment of Psoriasis Vulgaris: a Randomized, Double-Blind, Active-Controlled, Parallel Group Study.

Calcitriol, an Active Form of Vitamin D3, Mitigates Skin Barrier Dysfunction in Atopic Dermatitis NC/Nga Mice

Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids

Effect of daivobet® on the quality of life in chinese patients with stable psoriasis vulgaris: A multicenter, randomized, double-blind, positive controlled and parallel group study

Effect of calcipotriol betamethasone ointment on treatment of non-generalized vitiligo

Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Calcipotriol Scalp Solution In The Treatment Of Scalp Psoriasis: A Randomized, Controlled Trial Investigating Efficacy And Safety In A Chinese Population

1,25(OH)2D3 and its analogue calcipotriol inhibit the migration of human synovial and mesenchymal stromal cells in a wound healing model - A comparison with glucocorticoids

Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color

Clinical safety and efficacy of vitamin D3 analog ointment for treatment of obstructive meibomian gland dysfunction

Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.

Review of Calcipotriene and Betamethasone Dipropionate Cream in the Treatment of Psoriasis

The Vitamin D3 analogue calcipotriol suppresses CpG-activated TLR9-MyD88 signalling in murine plasmacytoid dendritic cells

Systematic review and practical guidance on the use of topical calcipotriol and topical calcipotriol with betamethasone dipropionate as long‐term therapy for mild‐to‐moderate plaque psoriasis

Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination

The Importance of the Formulation in the Treatment of Psoriasis: The Case of Calcipotriol/Betamethasone

Regulatory Effects of 1,25-dihydroxyvitamin D 3 and its Analogue MC903 on the Secretion of Interleukin-1α and IL-8 by Human Keratinocytes in vitro

Effects of Co-Application of Betamethasone 17-Valerate, from Different Formulations, with Tacrolimus Ointment on in Vitro Skin Permeation